Showing 6181-6190 of 10504 results for "".
- FDA Approves BMS' Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-bms-sotyktu-for-plaque-psoriasis/2461341/The FDA has approved Bristol Myers Squibb Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recom
- EADV News: ‘Healthy’ Suntan Myths Persist in Europehttps://practicaldermatology.com/news/eadv-news-healthy-suntan-myths-persist-in-europe/2461338/Fully eight in 10 Europeans believe tans are attractive with almost as many (73%) saying tans are healthy, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. Results from a survey, conducted by La Roche-Posay Laboratoires and
- Sklip Gets Approval to Test Skin Cancer Triage at Home Using AIhttps://practicaldermatology.com/news/sklip-gets-approval-to-test-skin-cancer-triage-at-home-using-ai/2461336/Sklip System AI for safe, effective and regulated consumer use
- DREAM Initiative from Allergan Aesthetics, SkinBetter Science Launches CARE Curriculumhttps://practicaldermatology.com/news/dream-initiative-from-allergan-skinbetter-science-launches-care-curriculum/2461334/The DREAM Initiative®, developed by Allergan Aesthetics and skinbetter science®, has supported the development of a racial equity curriculum for dermatology residency programs. The Curriculum f
- Allergan Aesthetics Hits Milestone: 100 Million Syringes of JUVÉDERM Shippedhttps://practicaldermatology.com/news/allergan-aesthetics-hits-milestone-100-million-syringes-of-juvederm-shipped/2461330/Drumroll, please…Allergan Aesthetics, an AbbVie company has produced and shipped 100 million syringes of JUVÉDERM products globally. Since its launch in 2000, the JUVÉDERM Collection of Fillers has grown to where its products are now avail
- EADV News: Tape Strip Test May Predict Eczema Risk in Babieshttps://practicaldermatology.com/news/eadv-news-tape-strip-test-may-predict-eczema-risk-in-babies/2461329/An immune biomarker in newborns may predict the subsequent onset and severity of paediatric atopic eczema, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The Barrier dysfunction in Atopic newBorns (BABY) study analyzed a c
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signali
- UK Study: Psoriasis Diagnoses in Primary Care Delayed by Up to 5 Yearshttps://practicaldermatology.com/news/uk-study-psoriasis-diagnoses-in-primary-care-delayed-by-up-to-5-years/2461322/Psoriasis may be underdiagnosed in UK primary care settings, according to research out of the University of Manchester in The British Journal of General Practice. Patients who are later diagnosed with psoriasis are twice as likely to be prescribed steroid or antifungal creams t
- New Partnership for Revision Skincare, RVL Pharmaceuticalshttps://practicaldermatology.com/news/new-partnership-for-revision-skincare-rvl-pharmaceuticals/2461320/With a goal to collaborate on a variety of marketing efforts within the medical aesthetics industry, Revision Skincare® and RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, are partnering to address what they see as significant unmet consumer needs. Revisions
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte